Biotechnology
Standigm named as a Tech Innovator in Generative AI in Drug Discovery use case
SEOUL, South Korea, Dec. 19, 2023 /PRNewswire/ -- Standigm
New Drug Application of Mabwell's 8MW0511 for Injection Accepted by NMPA
SHANGHAI, Dec. 19, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that the new drug application of its recombinant (yeast-secreted) human serum albumin-human granulocyte colony-stimulating factor (I) fusion protein for injec...
Roche navify digital solutions get excellent ratings from healthcare professionals in KLAS Research reports
* Healthcare professionals greatly value navify Tumor Board for improving tumour board meeting experiences, offering a holistic view of data, facilitating multidisciplinary team collaboration and optimising care decisions * navify POC Operations attains excellent ratings from health professio...
Innovent and AnHeart Therapeutics Announce the National Medical Products Administration of China Has Granted Taletrectinib (ROS1 Inhibitor) Priority Review Designation
ROCKVILLE, Md. and SUZHOU, China, Dec. 19, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology an...
Tsingke Congratulates iGEM 2023 SYSU-Software on Winning GOLD MEDAL for BioRocket Project
BEIJING and PARIS, Dec. 18, 2023 /PRNewswire/ -- The 2023 International Genetically Engineered Machine Competition (iGEM), the global synthetic biology competition, concluded onNovember 5, 2023. Over 7,000 students from high schools and universities, organized into more than 400 teams worldwide, ...
RNAimmune Receives Investigational New Drug Application Clearance from U.S. FDA for mRNA-Based Respiratory Syncytial Virus Vaccine RV-1770
GERMANTOWN, Md and GUANGZHOU, China, Dec. 18, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", Stock Code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today announc...
RemeGen Announces Continued Inclusion of Telitacicept and Disitamab Vedotin in China National Reimbursement Drug List, Ensuring Continuous Accessibility of Innovative Drugs for More Patients
YANTAI, China, Dec. 18, 2023 /PRNewswire/ -- RemeGen Co. Ltd.
Biocon Biologics Concludes Integration of Acquired Biosimilars Business in ~120 countries
10+ Emerging Markets, Japan & ANZ Transition in Final Phase KUALA LUMPUR, Malaysia, Dec. 18, 2023 /PRNewswire/ -- Biocon Biologics, a unique, fully integrated, global biosimilars company with a rich portfolio of insulins and monoclonal antibodies, has successfully concluded the integration of th...
GC Biopharma Announces US FDA Approval for ALYGLO™ (Immune Globulin Intravenous, Human-stwk) 10% Liquid for Adults with Primary Humoral Immunodeficiency (PI)
YOGIN, South Korea, Dec. 17, 2023 /PRNewswire/ -- GC Biopharma Corp (006280.KS) today announces that the US Food and Drug Administration (FDA) has approved ALYGLO (immune globulin intravenous, human-stwk) 10% Liquid, formerly referred to as "GC5107," for the treatment of adult patients aged 17...
Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications
ROCKVILLE, Md. and SUZHOU, China, Dec. 18, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...
First Patient Dosed in Clinical Trial of YOLT-201 for the Treatment of Hereditary ATTR-CM
SHANGHAI, Dec. 17, 2023 /PRNewswire/ -- YolTech Therapeutics today announced that the first patient has been dosed with YOLT-201, the company's firstin vivo genome editing candidate being developed as a single dose, potentially curative therapy for hereditary transthyretin amyloidosis with cardio...
SeekIn and OncoInv Collaborate to Expand the Global Accessibility of Multiple Cancer Detection Tests and Bridge Global Disparities in Cancer Care
SeekIn to Grant Oncolnv the Rights to Represent SeekIn's Comprehensive Range of Cancer Detection Tests in Twelve Countries to Provide Individuals with Accessible and Affordable Cancer Detection Tests SHENZHEN, China, Dec. 15, 2023 /PRNewswire/ -- SeekIn Inc, a leader in blood-based cancer early ...
Akeso Published Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-naïve Acute Myeloid Leukemia at ASH 2023
HONG KONG, Dec. 15, 2023 /PRNewswire/ -- Akeso published two phase Ib clinical results of its innovative CD47 monoclonal antibody ligufalimab (AK117) in combination with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) and treatment-naïve acute myeloid le...
Live from ASH 2023 | Oral Report Featuring Encouraging Data of Olverembatinib Combined with Reduced-Intensity Chemotherapy in Patients with Ph+ ALL Presented at the ASH Annual Meeting
SUZHOU, China and ROCKVILLE, Md., Dec. 14, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today thatProf. Xiaoyuan Gong of the Institute of Hemato...
BIOCHEETAH ANNOUNCES EXCLUSIVE LICENSING AND COMMERCIALISATION AGREEMENT WITH NIPPON KAYAKU FOR VECanDx™ IN JAPAN
SINGAPORE and TOKYO, Dec. 15, 2023 /PRNewswire/ -- BioCheetah Pte. Ltd. (Head Office:Singapore; CEO: Dr. Lee Kian Chung; hereinafter "BioCheetah") and Nippon Kayaku Co., Ltd. (Head Office:Tokyo; President: Mr. Atsuhiro Wakumoto; hereinafter "Nippon Kayaku") announce that the two companies have en...
Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted Antibody-Drug Conjugate (ADC)
* Nona Biosciences will receive a total of up to $53 Million in upfront and near-term payments, with the potential for milestones of up to$1.05 billion plus royalties. * Pfizer partnership expands Nona's global network of collaborations, reinforcing its commitment to providing cutting-edge te...
Expediting R&D Digitization for Life Sciences, ArisGlobal Introduces LifeSphere® NavaX™ - The Next-Generation Cognitive Computing Engine
NavaX will revolutionize the end-to-end Research and Development processes with the latest advanced technologies BOSTON, Dec. 15, 2023 /PRNewswire/ -- ArisGlobal, a market leader in Life Sciences technology and the creator of LifeSphere®, has today launched LifeSphere NavaX, a cutting-edge cogni...
Titans Gather, Future Embarks: The GenScript Biotech Global Forum coinciding with the 2024 J.P. Morgan Healthcare Conference in San Francisco to Convene 20+ KOLs, Exploring Disruptive Transformations and Infinite Opportunities in GCT
Keynote speaker Peter Marks to Deliver Address Free Early Bird Registration Closing Soon NANJING, China, Dec. 14, 2023 /PRNewswire/ -- Technological advancements continuously empower the life sciences. Gene and cell therapy (GCT), as breakthrough treatments, are turning the once-unreachable dre...
MGI Australia unveils its CEC with DCS Lab products featuring pioneering technology in DNA, Cell, and Spatial-omics Technology
Australia first market outside China to access revolutionary new capability
BRISBANE, Australia, Dec. 14, 2023 /PRNewswire/ -- MGI Australia, a
subsidiary ofMGI Tech Co. Ltd.
Antengene Announces Inclusion of XPOVIO® (selinexor) in 2023 China's National Reimbursement Drug List
SHANGHAI and HONG KONG, Dec. 14, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cance...
Week's Top Stories
Most Reposted
iKala Secures Over $20 Million in Series B+ Funding, Led by Chunghwa Telecom
[Picked up by 280 media titles]
2024-03-26 16:45Strengthening Interconnected Tourism Exchanges along the "21st Century Maritime Silk Road" Sanya Embarks on Tourism Marketing and Promotion Activities in Singapore
[Picked up by 276 media titles]
2024-03-22 21:46Chronicling ASEAN-China Friendship and Cooperation
[Picked up by 270 media titles]
2024-03-26 15:00Giti Tire Embarks on a Greener Future with New Chief Sustainability Officer
[Picked up by 263 media titles]
2024-03-25 09:00To jointly build equal, orderly multipolar world
[Picked up by 248 media titles]
2024-03-28 14:27